Physician profile
Terry Smith
NPI 1477960987
$2,186.91
in general payments reported to CMS, 2019-2025
21 companies · $512 in 2025
The $512 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.64 · 2022: $324 · 2023: $392 · 2024: $876 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733 · Education: $25.00 · Entertainment: $21.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.37 |
| Education | $25.00 |
| Entertainment | $21.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $340.18 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $328.33 | 2022-2025 | |
| Novo Nordisk INC | $323.29 | 2022-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $290.32 | 2023-2024 | |
| Lilly USA, LLC | $226.04 | 2022-2024 | Zepbound, Reyvow, Emgality |
| Emd Serono, INC. | $148.20 | 2024-2025 | Mavenclad |
| Mylan Specialty L.P. | $71.61 | 2021-2024 | Yupelri |
| Merz Pharmaceuticals, LLC | $52.37 | 2025 | Xeomin, Inbrija, Ampyra |
| Tactile Systems Technology INC | $51.89 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Idorsia Pharmaceuticals US INC | $51.12 | 2023 | Quviviq |
| Eisai INC. | $44.55 | 2024 | |
| Currax Pharmaceuticals LLC | $41.16 | 2023 | Nexletol, Contrave, Nexlizet |
| Ucb, INC. | $30.04 | 2025 | Rystiggo |
| Genzyme Corporation | $27.33 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.87 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $25.00 | 2024 | Pancreaze |
| Abbott Laboratories | $24.08 | 2025 | Freestyle Libre 3 |
| Grifols USA, LLC | $22.75 | 2024 | Gamunex-C |
| Genentech USA, INC. | $21.94 | 2025 | Ocrevus Zunovo |
| Optos, INC. | $21.40 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Tg Therapeutics, INC. | $19.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.